| Original language | English (US) |
|---|---|
| Pages (from-to) | e108-e110 |
| Journal | Diabetes care |
| Volume | 43 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2020 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialized Nursing
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use : Post hoc analyses of the LEADER trial. / Crowley, Matthew J.; McGuire, Darren K.; Alexopoulos, Anastasia Stefania; Jensen, Thomas Jon; Rasmussen, Søren; Saevereid, Hans A.; Verma, Subodh; Buse, John B.
In: Diabetes care, Vol. 43, No. 9, 09.2020, p. e108-e110.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use
T2 - Post hoc analyses of the LEADER trial
AU - Crowley, Matthew J.
AU - McGuire, Darren K.
AU - Alexopoulos, Anastasia Stefania
AU - Jensen, Thomas Jon
AU - Rasmussen, Søren
AU - Saevereid, Hans A.
AU - Verma, Subodh
AU - Buse, John B.
N1 - Funding Information: The views expressed in this article are the authors’ and do not necessarily represent those of their employers or funding agencies. Duality of Interest. Editorial support was provided by Watermeadow Medical under a contract from Novo Nordisk. D.K.M. reports personal feesforclinicaltrialleadershipfromAstraZeneca, Sanofi, Janssen, Boehringer Ingelheim, Merck & Co., Pfizer, Lilly USA, Novo Nordisk, Lexicon, Eisai Inc., GlaxoSmithKline, and Esperion and personal fees for consultancy from AstraZeneca, Sanofi, Eli Lilly and Company, Boehringer Ingelheim, Merck & Co., Pfizer, Novo Nordisk, Dynavax, Metavant, Applied Therapeutics, and Afimmune. T.J.J. is a full-time employee of and stockholder in Novo Nordisk. S.R. is a full-time employee of and stockholder in Novo Nordisk (Significant). H.A.S. is a full-time employee of Novo Nordisk. S.V. has received grants and research support from Amgen, Abbott, Bayer, Boehringer Ingelheim, Lilly, AstraZeneca, Janssen, Sanofi, HLS Therapeutics, and Merck. J.B.B.’s contracted consulting fees are paid to the University of North Carolina by Adocia, AstraZeneca, Dance Biopharm, Dexcom, Eli Lilly, Fractyl, GI Dynamics, Intarcia Therapeutics, Lexicon, MannKind, Metavention, NovaTarg, Novo Nordisk, Orexigen, PhaseBio, Sanofi, Senseonics, vTv Therapeutics, and Zafgen. He reports grant support from AstraZeneca, Eli Lilly and Company, Intarcia Therapeutics, Johnson & Johnson, Lexicon, Medtronic, Novo Nordisk, Sanofi, Theracos, Tolerion, and vTv Therapeutics; is a consultant to Cirius Therapeutics Inc., CSL Behring, Mellitus Health, Neurimmune AG, Pendulum Therapeutics, and Stability Health; and holds stock/options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health. No other potential conflicts of interest relevant to this article were reported. Author Contributions. M.J.C. helped develop the analyses, interpreted data, and wrote the manuscript. All other authors contributed to developing the analyses, interpreting data, and reviewing and editing the manuscript. S.R. was responsible for conducting the analyses. M.J.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Funding Information: Funding. M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). Funding Information: M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). The views expressed in this article are the authors? and do not necessarily represent those of their employers or funding agencies.
PY - 2020/9
Y1 - 2020/9
UR - http://www.scopus.com/inward/record.url?scp=85090093684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090093684&partnerID=8YFLogxK
U2 - 10.2337/dc20-0437
DO - 10.2337/dc20-0437
M3 - Letter
C2 - 32647053
AN - SCOPUS:85090093684
VL - 43
SP - e108-e110
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 9
ER -